Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 751 to 765 of 1305 results for long term conditions

  1. Mollii suit for spasticity (MIB100)

    NICE has a developed medtech innovation briefing on Mollii suit for spasticity .

  2. Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (HTG729)

    Evidence-based recommendations on digital technologies for assessing attention deficit hyperactivity disorder (ADHD).

  3. Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)

    This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.

  4. Migraine prophylaxis: flunarizine (ESUOM33)

    Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making

  5. Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)

    Evidence-based recommendations on necitumumab (Portrazza) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer in adults who have not had chemotherapy.

  6. Bortezomib for previously untreated mantle cell lymphoma (TA370)

    Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.

  7. Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

    Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.

  8. Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (TA1041)

    Evidence-based recommendations on durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer in adults.

  9. Hearing loss in adults: assessment and management (NG98)

    This guideline covers some aspects of assessing and managing hearing loss in primary, community and secondary care. It aims to improve the quality of life for adults with hearing loss by advising healthcare staff on assessing hearing difficulties, managing earwax and referring people for audiological or specialist assessment and management.

  10. Unintentional injuries in the home: interventions for under 15s (PH30)

    This guideline covers home safety assessments, supplying and installing safety equipment and providing education and advice. It aims to prevent unintentional injuries among all children and young people aged under 15 but, in particular, those living in disadvantaged circumstances.

  11. Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

    Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.

  12. VAAFT for treating anal fistulae (MIB102)

    NICE has developed a medtech innovation briefing (MIB) on VAAFT for treating anal fistulae .

  13. Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)

    Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.

  14. For people with common mental health conditions, what interventions are effective and cost effective in reducing recurrent short-term sickness absence and supporting return to work in the UK?

    people with common mental health conditions, what interventions are effective and cost effective in reducing recurrent...